Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial

The Lancet Infectious Diseases

Volumn 17, Issue 12, 2017, Pages 1255-1265

  Beigel, John H ^a   Bao, Yajing ^b   Beeler, Joy ^a   Manosuthi, Weerawat ^c,q   Slandzicki, Alex ^d,q   Dar, Sadia M ^e   Panuto, John ^f,q   Beasley, Richard L ^g,q   Perez Patrigeon, Santiago ^h   Suwanpimolkul, Gompol ^i,j,q   Losso, Marcelo H ^k,q   McClure, Natalie ^l   Bozzolo, Dawn R ^m   Myers, Christopher ⁿ   Holley, H Preston ^a   Hoopes, Justin ^o   Lane, H Clifford ^p   Hughes, Michael D ^b   Davey, Richard T ^p   Winnie, Michael ^q   Dinh, Dinh V ^q   Seethala, Raghu ^q   Garcia, Hiram ^q   Pouzar, Joe ^q   Seep, Michael ^q   Riffer, Ernie ^q   Bart, Belinda ^q   Dar, Sadia ^q   Hoppers, Melanie ^q   Rowe, Heather ^q   Wolfe, Cameron ^q   Desantis, Donna ^q   Baynton, Barr ^q   Markowitz, Norman ^q   Stearns, Zebediah A ^q   Cho, Josalyn ^q   Goisse, Marcy ^q   Wolf, Thomas A ^q   Kay, Jennifer ^q   Dharan, Nila ^q   Fitzgibbons, William ^q   Woodruff, Mark ^q   Bell, Todd ^q   Lenzmeier, Thomas ^q   Schooley, Robert ^q   Elie, Marie Carmelle ^q   Winokur, Patricia ^q   Finberg, Robert ^q   Hurt, Christopher ^q   Tebas, Pablo ^q   Sattler, Fred R ^q   Ampajwala, Madhavi ^q   Batts, Donald ^q   Bloch, Mark ^q   Moore, Richard ^q   Dwyer, Dominic ^q   Romo Garcia, Javier ^q   Patrigeon, Santiago Perez ^q   Zulueta, Ana Patricia Rodríguez ^q   Chetchotisakd, Ploenchan ^q   Ruxrungtham, Kiat ^q   Avihingsanon, Anchalee ^q   Ratanasuwan, Winai ^q   Lupo, Sergio ^q   Trape, Liliana ^q   Macias, Laura M ^q   Lopardo, Gustavo ^q   Barcelona, Laura ^q   Mykietuk, Analia ^q   Alzogaray, Maria F ^q   more..

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Bamrasnaradura Infectious Diseases Institute   (Thailand)

^d Clinical Research Solutions   (United States)

^e Clinical Research Solutions   (United States)

^f Clinical Research Solutions   (United States)

^g Health Concepts   (United States)

^h INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

ⁱ CHULALONGKORN UNIVERSITY   (Thailand)

^j THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^k HOSPITAL RAMOS MEJÍA   (Argentina)

^l Adamas Pharmaceuticals Inc   (United States)

^m SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

ⁿ NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^o AVR Laboratories LLC   (United States)

^p NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^q NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; OSELTAMIVIR; PLACEBO; RIBAVIRIN; VIRUS ANTIGEN; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARGENTINA; ARTICLE; ASTHMA; ATRIAL FIBRILLATION; AUSTRALIA; BLOODY DIARRHEA; BRONCHOSPASM; CELLULITIS; CLINICAL ASSESSMENT; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; COMPRESSION FRACTURE; CONTROLLED STUDY; DEHYDRATION; DELIRIUM; DIABETIC FOOT; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART FAILURE; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HOUSEKEEPING GENE; HUMAN; IMMUNE SYSTEM; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA B VIRUS; INJURY; INTENTION TO TREAT ANALYSIS; INTOXICATION; LIMIT OF QUANTITATION; LUNG EDEMA; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MEXICO; MONOTHERAPY; MULTICENTER STUDY; NASOPHARYNX; NAUSEA AND VOMITING; NUTRITIONAL DISORDER; ONLINE SYSTEM; PERSONALITY DISORDER; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROCEDURAL SITE REACTION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY DISTRESS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SHORT FORM 36; SKIN DISEASE; SPINE FRACTURE; SUPRAVENTRICULAR TACHYCARDIA; THAILAND; UNITED STATES; VIRUS GENE; VIRUS LOAD; VIRUS SHEDDING; CLINICAL TRIAL;

AMANTADINE; ANTIVIRAL AGENTS; ARGENTINA; AUSTRALIA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; MEXICO; OSELTAMIVIR; RIBAVIRIN; THAILAND; UNITED STATES;

EID: 85029765631     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30476-0     Document Type: Article

References (29)

1. US Centers for Disease Control and Prevention. http://www.cdc.gov/H1N1flu/recommendations.htm, 2009 (accessed June 20, 2010).
2. Bautista, E, Chotpitayasunondh, T, Gao, Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 362 (2010), 1708–1719.
3. Galegov, GA, Pushkarskaya, NL, Obrosova-Serova, NP, Zhdanov, VM, Combined action of ribovirin and rimantadine in experimental myxovirus infection. Experientia 33 (1977), 905–906.
4. Ilyushina, NA, Hay, A, Yilmaz, N, Boon, ACM, Webster, RG, Govorkova, EA, Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 52 (2008), 3889–3897.
5. Smee, DF, Hurst, BL, Wong, M-H, Bailey, KW, Morrey, JD, Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 53 (2009), 2120–2128.
6. Nguyen, JT, Hoopes, JD, Le, MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One, 5, 2010, e9332.
7. Hayden, FG, Douglas, RG, Simons, R, Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother 18 (1980), 536–541.
8. Govorkova, EA, Fang, H-B, Tan, M, Webster, RG, Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 48 (2004), 4855–4863.
9. Smee, DF, Bailey, KW, Morrison, AC, Sidwell, RW, Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 48 (2002), 88–93.
10. Smee, D, Hurst, B, Wong, M, et al. Effects of combinations of favipiravir (T-705) and oseltamivir on influenza A (H1N1, H3N2, and H5N1) virus infections in mice. Antimicrob Agents Chemother 54 (2010), 126–133.
11. Ilyushina, NA, Hoffmann, E, Salomon, R, Webster, RG, Govorkova, EA, Amantadine–oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther (Lond) 12 (2007), 363–370.
12. Galabov, AS, Simeonova, L, Gegova, G, Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir Chem Chemother 17 (2006), 251–258.
13. Leneva, IA, Roberts, N, Govorkova, EA, Goloubeva, OG, Webster, RG, The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 48 (2000), 101–115.
14. Smee, DF, Huffman, JH, Morrison, AC, Barnard, DL, Sidwell, RW, Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 45 (2001), 743–748.
15. Smee, DF, Wong, M-H, Bailey, KW, Sidwell, RW, Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother 17 (2006), 185–192.
16. Ilyushina, NA, Bovin, NV, Webster, RG, Govorkova, EA, Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70 (2006), 121–131.
17. Nguyen, JT, Hoopes, JD, Smee, DF, et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 53 (2009), 4115–4126.
18. Smith, S, Blanton, L, Kniss, K, et al. Update: influenza activity—United States. MMWR Morb Mortal Wkly Rep 64 (2015), 1342–1348.
19. Nguyen, JT, Smee, DF, Barnard, DL, et al. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One, 7, 2012, e31006.
20. Powers, JH, Guerrero, ML, Leidy, NK, et al. Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza. BMC Infect Dis, 16, 2016, 1.
21. Lins, L, Carvalho, FM, SF-36 total score as a single measure of health-related quality of life: scoping review. SAGE Open Med, 4, 2016 2050312116671725.
22. Seo, S, Englund, JA, Nguyen, JT, et al. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther 18 (2013), 377–386.
23. Kim, WY, Young Suh, G, Huh, JW, et al. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation. Antimicrob Agents Chemother 55 (2011), 5703–5709.
24. Kang, SJ, Park, KH, Kee, SJ, et al. Virological clearance rate of high-dose oseltamivir or triple-combination antiviral therapy in complicated 2009 pandemic influenza A (H1N1) infection. Jpn J Infect Dis 66 (2013), 425–427.
25. Barnard, DL, Animal models for the study of influenza pathogenesis and therapy. Antiviral Res 82 (2009), A110–A122.
26. Fritz, RS, Hayden, FG, Calfee, DP, et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 180 (1999), 586–593.
27. Lee, N, Chan, PK, Hui, DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 200 (2009), 492–500.
28. Ison, MG, de Jong, MD, Gilligan, KJ, et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 201 (2010), 1654–1662.
29. US Food and Drug Administration. Guidance for industry—influenza: developing drugs for treatment and/or prophylaxis, 2011, US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Silver Spring, MD.